CNS Disorders  >>  Invega Sustenna (paliperidone palmitate extended-release 1-month injection)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

4 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J
NCT01606254: A Pharmacokinetic and Safety Study of Paliperidone Palmitate (JNS010) in Participants With Schizophrenia

Completed
2
56
Japan
Paliperidone palmitate, JNS010
Janssen Pharmaceutical K.K.
Schizophrenia
04/08
04/08
NCT01450514 / 2011-004494-81: POC Study of Pipamperone Added to Stable Treatment With RIS or PAL in Chronic Schizophrenia

Completed
2
7
Europe
Pipamperone, Risperdal, Invega and Xeplion, Placebo
PharmaNeuroBoost N.V.
Chronic Schizophrenia, Schizoaffective Disorder
11/12
12/12
NCT04754750: Differences in Schizophrenia With One-month and 3-month Paliperidone Palmitate Treatment

Completed
1/2
72
NA
Paliperidone Palmitate 156 MG/ML Prefilled Syringe [Invega], Sustenna, Paliperidone Palmitate 546 MG Intramuscular Suspension, Extended Release [INVEGA TRINZA], Trinza
Calo Psychiatric Center
Schizophrenics
06/17
06/17
NCT03425552: A Clinical Study to Evaluate the Bioavailability Between Two Products Containing Paliperidone 100 mg in the Form of a Prolonged Release Suspension for Injection in Patients With Schizophrenia Who Are Already Stabilized in This Treatment

Completed
1/2
70
RoW
Paliperidone, Xeplion
Pharmathen S.A.
Schizophrenia
05/19
05/19

Download Options